Candel Therapeutics, Inc.
HealthcareNASDAQ:CADL · NASDAQ Global Market
+$0.40 today
Vol 1.36M · Avg 1.83M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.5%
avg -53.2%
ROIC
-41.4%
avg -46.6%
ROA
-30.5%
avg -43.3%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -43.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul-Peter Tak FOCIS | President, Chief Executive Officer & Director | $1.03M | — | 65 | $629,000.00 | 1.15% |
Seshu Tyagarajan | Chief Technical & Development Officer | $613,231.00 | — | 58 | $154,000.00 | 0.28% |
Francesca Barone | Chief Scientific Officer | $497,312.00 | — | 48 | $232,000.00 | 0.42% |
Charles Schoch | Senior VP, CFO, Treasurer & Secretary | $412,032.00 | — | 41 | $232,000.00 | 0.42% |
William Nichols Garrett | Chief Medical Officer | — | — | 57 | $136,500.00 | 0.25% |
Ileen Winick | Chief People Officer | — | — | — | — | — |
Susan Stewart | Chief Regulatory Officer | — | — | 65 | $20,000.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$3.00M
Sells
2
$10,476.50
Net Sentiment
+$2.99M
Net buying
Most Active
Nichols William Garrett
2 transactions
Analysis
Insiders reported 1 buys worth $3.00M and 2 sells worth $10,476.50 over the last 12 months. That adds up to net buying of $2.99M. Nichols William Garrett was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Genelux Corporation
NASDAQ:GNLX
$111.35M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Immutep Limited
NASDAQ:IMMP
$53.60M
Mereo BioPharma Group plc
MREO
$48.68M
Who manages CADL?
Candel Therapeutics, Inc. (CADL) lists 7 active executives. The top listed executive is Francesca Barone, Chief Scientific Officer.
Are CADL insiders buying or selling?
Recent insider activity shows net buying of $18.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.